Home » Stocks » CYCC

Cyclacel Pharmaceuticals, Inc. (CYCC)

Stock Price: $7.43 USD 0.07 (0.95%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $7.42 -0.01 (-0.14%) Jan 22, 7:54 PM
Market Cap 36.14M
Revenue (ttm) 150,000
Net Income (ttm) -8.15M
Shares Out 4.86M
EPS (ttm) -3.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $7.43
Previous Close $7.36
Change ($) 0.07
Change (%) 0.95%
Day's Open 7.38
Day's Range 7.23 - 7.52
Day's Volume 145,097
52-Week Range 3.21 - 15.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investm...

Other stocks mentioned: CYCCP
GlobeNewsWire - 3 weeks ago

BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing inno...

Other stocks mentioned: CYCCP
Seeking Alpha - 2 months ago

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: CYCCP
GlobeNewsWire - 2 months ago

BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innova...

Other stocks mentioned: CYCCP
GlobeNewsWire - 2 months ago

A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib A patient with MCL1 amplified endometrial cancer achi...

Other stocks mentioned: CYCCP
GlobeNewsWire - 3 months ago

BERKELEY HEIGHTS, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innov...

Other stocks mentioned: CYCCP
GlobeNewsWire - 3 months ago

BERKELEY HEIGHTS, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innov...

Other stocks mentioned: CYCCP
GlobeNewsWire - 4 months ago

BERKELEY HEIGHTS, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing inn...

Other stocks mentioned: CYCCP
Seeking Alpha - 5 months ago

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET - - Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -

Other stocks mentioned: CYCCP
GlobeNewsWire - 5 months ago

BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing in...

Other stocks mentioned: CYCCP
Zacks Investment Research - 5 months ago

Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.

GlobeNewsWire - 6 months ago

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against

Other stocks mentioned: CYCCP
Seeking Alpha - 8 months ago

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: CYCCP
GlobeNewsWire - 8 months ago

- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET -

Other stocks mentioned: CYCCP
GlobeNewsWire - 8 months ago

BERKELEY HEIGHTS, N.J., April 24, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing i...

Other stocks mentioned: CYCCP
24/7 Wall Street - 9 months ago

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) shares were crushed on Tuesday after the company announced the pricing of a secondary offering.

Other stocks mentioned: CYCCP
GlobeNewsWire - 9 months ago

BERKELEY HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing i...

Other stocks mentioned: CYCCP
Benzinga - 9 months ago

Shares of nanocap biopharma Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) were ripping higher Monday following the announcement of a partnership to study two of its drugs to treat complications ...

GlobeNewsWire - 9 months ago

-Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury- -Evaluation of Fadraciclib and Seliciclib to Promote Apoptosi...

Other stocks mentioned: CYCCP
GlobeNewsWire - 9 months ago

BERKELEY HEIGHTS, N.J., April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing i...

Other stocks mentioned: CYCCP
Seeking Alpha - 10 months ago

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

GlobeNewsWire - 1 year ago

CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies

Other stocks mentioned: CYCCP
Seeking Alpha - 1 year ago

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing i...

Other stocks mentioned: CYCCP
GlobeNewsWire - 1 year ago

BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing in...

Other stocks mentioned: CYCCP
GlobeNewsWire - 1 year ago

BERKELEY HEIGHTS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing i...

Other stocks mentioned: CYCCP
Seeking Alpha - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2018 Results - Earnings Call Transcript

About CYCC

Cyclacel Pharmaceuticals, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemia... [Read more...]

Industry
Biotechnology
Founded
1992
CEO
Spiro Rombotis
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
CYCC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CYCC stock is "Strong Buy." The 12-month stock price forecast is 21.33, which is an increase of 187.08% from the latest price.

Price Target
$21.33
(187.08% upside)
Analyst Consensus: Strong Buy